Demyelinating Diseases
Conditions
Keywords
All selective craniotomy
Brief summary
Recent developments in the understanding of stem- and progenitor cell differentiation raises hopes that brain damage in chronic neurological diseases may become repaired by systemic or focal transplantation of such cells. Clinical trials of stem- or progenitor cell transplantation in multiple sclerosis are currently premature. The researchers developed a protocol for human oligodendrocyte progenitor cell culture from human brain for the treatment of demyelinating disease.
Detailed description
Oligodendrocyte progenitor cell line were cultures and will be transplanted into the patient with Multiple sclerosis.
Interventions
PROCEDUREOligodendrocyte progenitor cell culture/craniotomy
Oligodendrocyte progenitor cell culture protocol of Rajavithi Hospital will be apply
Sponsors
Department of Medical Services Ministry of Public Health of Thailand
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Intervention model description
Cell culture
Eligibility
Sex/Gender
ALL
Age
20 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Male or female 20-65 years of age * Informed consent * Has elective craniotomy surgery
Exclusion criteria
* HIV, hepatitis, and other central nervous system (CNS) infections * Dementia, Alzheimer disease, and neurodegenerative disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of oligodendrocyte progenitor cell differentiation | one month |
Countries
Thailand
Outcome results
None listed